A detailed history of Vident Advisory, LLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 16,084 shares of VCYT stock, worth $588,513. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,084
Previous 16,852 4.56%
Holding current value
$588,513
Previous $373 Million 6.67%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$18.86 - $23.55 $14,484 - $18,086
-768 Reduced 4.56%
16,084 $349 Million
Q1 2024

May 14, 2024

BUY
$21.0 - $29.1 $22,701 - $31,457
1,081 Added 6.85%
16,852 $373 Million
Q4 2023

Feb 14, 2024

SELL
$19.72 - $28.68 $6,527 - $9,493
-331 Reduced 2.06%
15,771 $434 Million
Q3 2023

Feb 21, 2024

BUY
$22.33 - $29.92 $198,625 - $266,138
8,895 Added 56.4%
24,666 $551 Million
Q3 2023

Nov 14, 2023

BUY
$22.33 - $29.92 $359,557 - $481,771
16,102 New
16,102 $360 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.62B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.